Type-II Variation [Study As­sess­ment]

posted by Helmut Homepage – Vienna, Austria, 2024-07-02 11:37 (15 d 16:16 ago) – Posting: # 24053
Views: 755

Hi QA,

IMHO, this is Type-II Variation (according to the EMA’s Q&Aa change that may have a significant impact on the quality, safety or efficacy of the medicinal product’), and, thus, an in-vivo study is required. See also EC 2013/C 223/01, Section B.II.b.3.b).

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
 Admin contact
23,107 posts in 4,858 threads, 1,644 registered users;
51 visitors (0 registered, 51 guests [including 5 identified bots]).
Forum time: 03:54 CEST (Europe/Vienna)

All paid jobs absorb and degrade the mind.    Aristotle

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz